The acquisition reflects Cardinal’s expanded focus on urology in pursuit of higher growth margin versus drug distribution.

Cardinal Health logged slightly higher profit and revenue in its fiscal fourth quarter, as recent acquisitions helped to offset lingering malaise stemming from its OptumRx contract expiration.

Cardinal Health's Specialty Alliance will acquire Solaris Health for $1.9 billion, enhancing its urology capabilities. The acquisition aligns with Cardinal's strategic focus on specialty growth and is expected to close by the end of 2025.